KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Esperion Therapeutics (ESPR) Other Gross PP&E Adjustments (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Other Gross PP&E Adjustments readings, the most recent being -$27.1 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 7.38% to -$27.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$27.1 million, a 7.38% increase, with the full-year FY2025 number at -$27.1 million, up 7.38% from a year prior.
  • Other Gross PP&E Adjustments hit -$27.1 million in Q4 2025 for Esperion Therapeutics, down from -$3.3 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$730000.0 in Q3 2022 to a low of -$29.2 million in Q4 2024.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$4.6 million (2021), compared with a mean of -$9.6 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: soared 84.87% in 2022 and later tumbled 563.26% in 2024.
  • Esperion Therapeutics' Other Gross PP&E Adjustments stood at -$21.9 million in 2021, then fell by 12.07% to -$24.6 million in 2022, then dropped by 14.3% to -$28.1 million in 2023, then dropped by 4.17% to -$29.2 million in 2024, then rose by 7.38% to -$27.1 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$27.1 million (Q4 2025), -$3.3 million (Q3 2025), and -$4.2 million (Q2 2025) per Business Quant data.